Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2020 Oct 15;40(12):e322–e335. doi: 10.1161/ATVBAHA.119.314238

Figure 7. PKC inhibition recapitulates reduced ox-LDL accumulation observed in Epac1−/− BMDMs.

Figure 7.

(A) Representative images of ORO stained WT and Epac1−/− BMDMs, pretreated with vehicle or PKC inhibitor GF109203X (3 μM) for 30 min, then stimulated with ox-LDL (40 μg/mL) for 48 h (N = 4 for each genotype). (B) Quantification of ORO stained BMDMs by methanol elution. Data are presented as mean ± SEM.